논문 및 학회자료

Safety Evaluation of FM101, an A3 Adenosine Receptor Modulator, in Rat, for Developing as Therapeutics of Glaucoma and Hepatitis. EXCLI Journal. 2020

Admin │ 2020-06-11

HIT

267

이전글 A randomized, double-blind, placebo-controlled, first-in-human single ascending ...
다음글 Preclinical characterization of FM101, a first-in-class A3 adenosine receptor mo...